-
公开(公告)号：US20170355689A1
公开(公告)日：2017-12-14
申请号：US15689286
申请日：2017-08-29
Applicant: Bristol-Myers Squibb Company
Inventor： RICO LAVOIE , John A. Bender , Zhong Yang , Makonen Belema , Omar D. Lopez , Qi Chen , Gan Wang , Piyasena Hewawasam
IPC: C07D309/06 , C07D487/04 , C07D403/10 , A61K31/4184 , A61K31/4375 , A61K31/498 , A61K31/4545 , A61K31/5377 , C07D401/14 , C07D403/14 , C07D405/14 , A61K31/437 , A61K31/4709 , A61K45/06 , C07D413/14 , C07D471/04 , A61K31/4178 , A61K31/4985
CPC classification number: C07D309/06 , A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US09770439B2
公开(公告)日：2017-09-26
申请号：US14753564
申请日：2015-06-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Piyasena Hewawasam , Omar D. Lopez , Yong Tu , Alan Xiangdong Wang , Ningning Xu , John F. Kadow , Nicholas A. Meanwell , Samayamunthula Venkata Satya Arun Kumar Gupta , Indasi J. Gopi Kumar , Suresh Kumar Ponugupati , Makonen Belema
IPC: A61K31/415 , A61K31/535 , C07D471/04 , A61K31/40 , A61K31/44 , A61K31/4178 , A61K38/21 , A61K31/4245 , A61K31/4725 , A61K31/7056 , A61K45/06 , C07D233/64 , C07D403/14 , C07D405/14 , C07D493/08 , A61K31/437 , A61K31/439 , A61K31/402 , A61K31/4184 , A61K31/4188 , A61K31/454 , A61K31/4545 , A61K31/519 , A61K31/5365 , A61K31/5377 , A61K31/695 , A61K38/20
CPC classification number: A61K31/4178 , A61K31/402 , A61K31/4184 , A61K31/4188 , A61K31/4245 , A61K31/437 , A61K31/439 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/519 , A61K31/5365 , A61K31/5377 , A61K31/695 , A61K31/7056 , A61K38/2013 , A61K38/204 , A61K38/208 , A61K38/21 , A61K45/06 , C07D233/64 , C07D403/14 , C07D405/14 , C07D493/08 , A61K2300/00
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
-
公开(公告)号：US09758487B2
公开(公告)日：2017-09-12
申请号：US15194980
申请日：2016-06-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Gan Wang , Lawrence G. Hamann
IPC: A61K38/20 , A61K31/4164 , A61K31/517 , A61K31/715 , A61K38/46 , A61P31/00 , C07D403/02 , C07D401/00 , C07D233/64 , C07D401/14 , C07D403/14 , A61K31/4178 , A61K45/06 , C07D405/14 , C07D413/14 , C07D409/14 , C07D417/14
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US09303007B2
公开(公告)日：2016-04-05
申请号：US14806964
申请日：2015-07-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Omar D. Lopez
IPC: C07D309/06
CPC classification number: C07D309/06 , A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US20130115193A1
公开(公告)日：2013-05-09
申请号：US13672266
申请日：2012-11-08
Applicant: Bristol-Myers Squibb Company
Inventor： Rico Lavoie , John A. Bender , Zhong Yang , Makonen Belema , Omar D. Lopez , Qi Chen , Gan Wang , Piyasena Hewawasam
IPC: C07D403/14 , A61K31/4545 , C07D401/14 , A61K31/437 , C07D471/04 , A61K31/4985 , C07D487/04 , C07D405/14 , A61K31/498 , A61K31/4178 , A61K31/4375 , A61K31/4709 , A61K31/5377 , C07D413/14 , C07D403/10 , A61K45/06 , A61K31/4184
CPC classification number: C07D309/06 , A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
Patent Agency Ranking
公开(公告)号：US09717712B2
公开(公告)日：2017-08-01
申请号：US14904817
申请日：2014-07-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alan Xiangdong Wang , Omar D. Lopez , Yong Tu , Makonen Belema
IPC: A61K31/415 , A61K31/4184 , A61K31/4178 , A61K38/21 , A61K31/7056
CPC classification number: A61K31/4184 , A61K31/4178 , A61K31/7056 , A61K38/21 , A61K38/212 , A61K2300/00
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
-
7.发明申请Combinations Comprising Tricyclohexadecahexaene Derivatives for Use in the Treatment of Hepatitis C Virus 审中-公开包含用于治疗丙型肝炎病毒的三环十六碳六烯衍生物的组合公开(公告)号：US20160166547A1
公开(公告)日：2016-06-16
申请号：US14904817
申请日：2014-07-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alan Xiangdong Wang , Omar D. Lopez , Yong Tu , Makonen Belema
IPC: A61K31/4184 , A61K38/21 , A61K31/7056 , A61K31/4178
CPC classification number: A61K31/4184 , A61K31/4178 , A61K31/7056 , A61K38/21 , A61K38/212 , A61K2300/00
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
Abstract translation: 本公开通常涉及抗病毒化合物，更具体地涉及可以抑制丙型肝炎病毒（HCV）编码的NS5A蛋白的功能的化合物的组合，包含这些组合的组合物，以及用于抑制NS5A的功能的方法 蛋白。
-
公开(公告)号：US09227961B2
公开(公告)日：2016-01-05
申请号：US14488990
申请日：2014-09-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: C07D401/14 , C07D403/14 , C07D413/14 , C07D233/64 , C07D405/14 , A61K31/4178 , A61K45/06
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US20140205564A1
公开(公告)日：2014-07-24
申请号：US14221774
申请日：2014-03-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jeffrey Lee Romine , Denis R. St. Laurent , Makonen Belema , Lawrence B. Snyder , Lawrence G. Hamann , John F. Kadow , Jayne Kapur , Andrew C. Good , Omar D. Lopez , Rico Lavoie , John A. Bender
IPC: C07D403/14 , A61K45/06 , A61K38/21 , A61K31/7056 , A61K31/4725 , C07D405/14 , A61K31/454 , C07D413/14 , A61K31/422 , A61K31/4184 , A61K38/20
CPC classification number: C07D403/14 , A61K31/4184 , A61K31/422 , A61K31/454 , A61K31/4725 , A61K31/7056 , A61K38/2013 , A61K38/204 , A61K38/208 , A61K38/21 , A61K38/212 , A61K45/06 , C07D405/14 , C07D413/14
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Abstract translation: 本公开涉及用于治疗丙型肝炎病毒（HCV）感染的化合物，组合物和方法。 还公开了含有这些化合物的药物组合物和使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US08735398B2
公开(公告)日：2014-05-27
申请号：US13670691
申请日：2012-11-07
Applicant: Bristol-Myers Squibb Company
Inventor： Omar D. Lopez , Denis R. St. Laurent , Jason Goodrich , Jeffrey Lee Romine , Michael Serrano-Wu , Fukang Yang , Ramesh Kakarla , Xuejie Yang , Yuping Qiu , Lawrence B. Snyder
IPC: C07D249/08 , C07D231/12 , C07D413/14 , C07D233/58 , A61K31/4196 , A61K31/4245 , A61K31/415
CPC classification number: A61K31/415 , A61K31/4196 , A61K31/4245 , C07D231/12 , C07D233/58 , C07D233/64 , C07D249/06 , C07D249/08 , C07D249/12 , C07D263/32 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.
Abstract translation: 本公开一般涉及抗病毒化合物，更具体地涉及可以抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白的功能的化合物，包含这些化合物的组合物，以及用于抑制NS5A蛋白功能的方法。
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.081 seconds)
